Metis Foundation

RANDOMIZED CONTROLLED TRIAL OF IVABRADINE IN LONG-HAUL COVID-19

MILITARY CARDIOVASCULAR OUTCOMES RESEARCH (MICOR) CORE

MILITARY CARDIOVASCULAR OUTCOMES RESEARCH (MICOR)

CELLULAR THERAPIES FOR THE TREATMENT OF ACUTE RADIATION SYNDROME COMBINED WITH TRAUMATIC INJURY

RESTORATION OF THE FUNCTIONAL AESTHETIC CRANIOFACIAL ENVELOPE AND EXTREMITIES

DEVELOPMENT AND VALIDATION OF A SMART-MEMORY INTRAVITREAL TAMPONADE STENT FOR RETINAL DETACHMENT IN COMBAT OCULAR TRAUMA

MILITARY CARDIOVASCULAR OUTCOMES RESEARCH (MICOR) ELECTROCARDIOGRAM RISK ASSESSMENT TO PREVENT SUDDEN CARDIAC EVENTS (ERASE) PROGRAM

MILITARY CARDIOVASCULAR OUTCOMES RESEARCH (MICOR)- FY24 CORE

MILITARY CARDIOVASCULAR OUTCOMES RESEARCH (MICOR)

DEVELOPMENT OF NANOPHARMACEUTICAL THERAPY FOR COMBAT-RELATED PROLIFERATIVE VITREORETINOPATHY. NEW AWARD.

A PROSPECTIVE STUDY USING SUPRASDRMA IN PROMOTING HEALING AND REDUCING THE TIME TO GRAFTING OF FULL-THICKNESS WOUNDS TO ACCELERATE RETURN TO DUTY

ANTIBIOTIC CONCENTRATIONS AFTER MASSIVE TRANSFUSION (ACME) STUDY

ELECTROCEUTICAL DRESSING AGAINST TRAUMATIC AND BURN WOUND BIO FILM INFECTION

SPRAYABLE ANTIMICROBIAL AND REGENERATION PROMOTING FOAM SCAFFOLD FOR THE TREATMENT OF NON-HEALING SKIN WOUNDS

A NEW PLATFORM FOR BURN TREATMENT AND FOR DELAYED EVACUATION OF SERVICE MEMBERS

IMPROVING SEVERE BURN RESUSCITATION OUTCOMES WITH ICATIBANT, AN FDA-APPROVED, SPECIFIC BRADYKININ B2 RECEPTOR ANTAGONIST

A NEW PARADIGM IN TRAUMA CARE: THE LETHAL TETRAD OF INJURY-INDUCED HYPOCALCEMIA, ACIDOSIS, COAGULOPATHY, AND HYPOTHERMIA

NOVEL THERAPEUTICS TARGET INNATE IMMUNE RESPONSES FOR TREATING MULTIPLE ORGAN FAILURE IN SEVERE POLYTRAUMA DURING PROLONGED CASUALTY CARE

AN AUTONOMOUS DYNAMIC SENSOR TECHNOLOGY FOR PATHOPHYSIOLOGICAL MONITORING AND RESUSCITATIVE GUIDANCE IN ACTIVE DENIAL ENVIRONMENTS

SPERRY MICRO-CORING SYSTEM: AUTOMATED FULL-THICKNESS SKIN MICROCOLUMNS IN DERMAL REGENERATION TEMPLATES FOR 'DONOR-FREE' SKIN RENEWAL IN PROLONGED FIELD CARE.

SUPRATHEL USE DURING PROLONGED FIELD CARE TO PROMOTE HEALING AND REDUCE THE NEED FOR GRAFTING OF BURN WOUNDS.

PORTABLE INTEGRATED OPTIC BIOSENSORS FOR RECOGNIZING EARLY POTENTIAL LOSS OF AMPUTATED NATIVE TISSUE (REPLANT) IN RECONSTRUCTION OF THE COMPLEX UPPER EXTREMITY

PROSTATE-SPECIFIC ANTIANDROGEN THERAPY FOR LOCALIZED PROSTATE CANCER

SALVAGE, PRESERVATION, AND ADVANCED RESUSCITATION THROUGH ENDOTHELIAL STABILIZATION (SPARES)

TAS::97 0130::TAS MESENCHYMAL STEM CELL DERIVED EXOSOMES AS A MODULATOR OF PERIPHERAL NERVE REGENERATION/REPAIR

A RANDOMIZED, PROSPECTIVE, WITHIN-PATIENT, CONTROLLEDCLINICAL STUDY TO INVESTIGATE FULL THICKNESS SKIN TISSUE COLUMNS AS A NOVEL SKIN R.

PREVENTION OF CHRONIC REJECTION IN COMPOSITE TISSUE AND SOLID ORGAN TRANSPLANTATION

PFAS AND OTHER TOXIC MILITARY EXPOSURES AND PANCREATIC CANCER RISK IN A MILITARY POPULATION

REMOTE MONITORING OF CARDIOPULMONARY FUNCTION WITH A RUGGED WEARABLE TISSUE OXIMETER

NOVEL ANTIMICROBIAL EXTERNAL FIXATION DEVICE TO COMBAT PIN TRACK INFECTION

NANOPARTICULATE SCRUB TO REMOVE BIOFILM BACTERIA FROM THE SKIN/IMPLANT INTERFACE IN OSSEOINTEGRATED IMPLANTS.

THE BIOPSYCHOSOCIAL ASPECTS OF CHRONIC PAIN PRE AND POST FUNCTIONAL RESTORATION PROGRAM WITHIN THE SAMMC INTERDISCIPLINARY PAIN MANAGEMENT CLINIC

DEVELOPING WARM, FRESH, WHOLE BLOOD TRANSFUSION SKILLS FOR COMBAT MEDICS

IMPLANTATION OF FULL-THICKNESS SKIN COLUMNS TO DECREASE HYPERTROPHIC SCAR FORMATION AFTER DEEP PARTIAL THICKNESS BURNS

INVESTIGATION OF A NEW CHEMICAL AGENT FOR USE IN COVERAGE PRODUCTS TO TREAT AND PREVENT LARGE SECOND- AND THIRD-DEGREE BURN WOUND INFECTIONS FOR PROLONGED FIELD CARE APPLICATIONS

MIRCOFRAGMENTED ADIPOSE TISSUE AND BLOOD PLASMA-BASED HYDROGELS FOR TREATMENT OF COMBAT-ASSOCIATED BURN INJURIES

EFFICACY OF TOPICAL CANNABINOID ANALGESICS FOR BURN WOUND HEALING.

A MULTI-MODAL APPROACH TO REDUCE VCA IMMUNOGENICITY AND IMPROVE FUNCTIONAL OUTCOME

BISPECIFIC ANTIBODY TO TARGET FVIII-SPECIFIC B CELLS - ABSTRACT: THE ANTIBODY RESPONSE TO FACTOR VIII (FVIII) IN HEMOPHILIA A PATIENTS IS A CRITICAL PROBLEM SINCE THESE ANTIBODIES (CALLED INHIBITORS) BLOCK THE THERAPEUTIC ACTIVITY OF FVIII. THE CURRENT TREATMENT FOR INHIBITOR PATIENTS, CALLED IMMUNE TOLERANCE INDUCTION (ITI) IS EXPENSIVE AND FAILS IN MANY CASES. THUS, IMPROVED METHODS TO ELIMINATE INHIBITORS IS AN UNMET NEED. WE PROPOSE TO ACHIEVE THIS BY DIRECT TARGETING AND DELETION OF FVIII-SPECIFIC B CELLS. OUR LAB HAS DEVELOPED SEVERAL CELLULAR APPROACHES TO PREVENT AND REVERSE INHIBITOR FORMATION, INCLUDING THE CREATION OF NOVEL ENGINEERED FVIII-SPECIFIC REGULATORY OR CYTOTOXIC T CELLS. THESE HUMAN AND MOUSE T CELLS WERE ENGINEERED TO EXPRESS FVIII- SPECIFIC CHIMERIC RECEPTORS OR FVIII ANTIGEN DOMAINS, THE LATTER WHICH CAN INTERACT WITH NAÏVE OR MEMORY B-CELL PRECURSORS OF FVIII-SPECIFIC PLASMA CELLS TO BLOCK OR REVERSE INHIBITOR FORMATION. WE NAMED THESE LATTER CELLS “BAR” FOR B-CELL-TARGETING ANTIBODY RECEPTOR CELLS. THESE PERSONALIZED CELLULAR THERAPIES ARE EFFECTIVE AT SUPPRESSING FVIII-SPECIFIC B-CELL RESPONSES. OUR OVERALL GOAL HEREIN IS TO BUILD ON OUR SUCCESSFUL CELLULAR APPROACHES BY CREATING PROTEIN THERAPEUTICS THAT WOULD TARGET AND ELIMINATE FVIII-SPECIFIC B CELLS, USING NEW B-CELL RECEPTOR TRANSGENICS SPECIFIC TO A FVIII DOMAIN. THUS, WE HAVE DESIGNED CHIMERIC IMMUNE CONJUGATES THAT LINK CYTOTOXIC CD8 T CELLS WITH FVIII-SPECIFIC B CELLS VIA EXPRESSION OF FVIII DOMAINS, AS IN THE “BAR” APPROACH ABOVE. WE PROPOSE TO EVALUATE THEM FOR CYTOTOXICITY AGAINST FVIII-SPECIFIC B CELLS, AND TO PROVIDE PROOF OF PRINCIPLE TO MODULATE ANTI-FVIII RESPONSES IN VITRO AND IN VIVO IN A MOUSE MODEL OF HEMOPHILIA A. THESE IMMUNOCONJUGATES HAVE THE POTENTIAL TO ELIMINATE ANTI-FVIII INHIBITORS IN PATIENTS. 1

SINGLE SESSION CBT-INFORMED TREATMENT FOR LOSS OF CONTROL EATING DURING PREGNANCY: A PILOT FEASIBILITY STUDY - ABSTRACT AFFECTING 50% OF PREGNANT WOMEN IN THE US, EXCESS GESTATIONAL WEIGHT GAIN (EGWG) HAS BROAD AND LASTING ADVERSE IMPACTS ON BOTH MATERNAL AND CHILD HEALTH. A POTENTIALLY KEY MODIFIABLE TARGET FOR THE PREVENTION OF EGWG IS LOSS-OF-CONTROL (LOC) EATING, A DISORDERED EATING BEHAVIOR CHARACTERIZED BY THE PERCEIVED EXPERIENCE OF BEING UNABLE TO CONTROL WHAT OR HOW MUCH ONE IS EATING, REGARDLESS OF THE AMOUNT OF FOOD CONSUMED. THERE IS A STRONG EVIDENCE BASE SUPPORTING COGNITIVE-BEHAVIORAL THERAPY (CBT) APPROACHES FOR REDUCING LOC EATING, YET THERE ARE CURRENTLY NO PREGNANCY-FOCUSED INTERVENTIONS THAT TARGET LOC EATING. HOWEVER, CBT CAN BE RESOURCE-INTENSIVE, COSTLY, LASTS SEVERAL MONTHS IN DURATION, AND OFTEN REQUIRES PROVIDERS WITH SPECIALIZED TRAINING. GIVEN THESE CRITICAL CHALLENGES, DEVELOPING NOVEL, BRIEF, AND EVIDENCE-BASED APPROACHES TO TARGETING LOC EATING DURING PREGNANCY IS A CRUCIAL STEP TOWARDS ADDRESSING EGWG. VIRTUAL SINGLE-SESSION INTERVENTIONS (SSI) THAT DELIVER THE CENTRAL THEORY-DRIVEN COMPONENTS OF LONGER INTERVENTIONS REPRESENT AN INNOVATIVE APPROACH THAT BALANCES TIME AND RESOURCES WITH PUBLIC HEALTH IMPACT, YET HAVE NOT BEEN ADAPTED FOR LOC EATING OR PREGNANCY. TO FILL THIS GAP, I DESIRE TO BECOME A LEADING INDEPENDENT INVESTIGATOR WITH A RESEARCH PROGRAM FOCUSED ON THE DEVELOPMENT, IMPLEMENTATION, AND EVALUATION OF INTERVENTIONS TO PREVENT AND TREAT EATING AND WEIGHT BEHAVIORS, BUT REQUIRE ADDITIONAL TRAINING. THE NIH MENTORED-PATIENT ORIENTED CAREER DEVELOPMENT AWARD WILL PROVIDE PROTECTED TIME TO SEEK THIS TRAINING AND FURTHER MY SKILLS AND ABILITY TO IMPLEMENT THE PROPOSED RESEARCH. MY SHORT-TERM TRAINING GOALS ARE TO DEVELOP ADVANCED EXPERTISE IN (1) MIXED-METHODS AND QUALITATIVE RESEARCH DESIGN, (2) IMPLEMENTATION SCIENCE THEORY AND METHODS, (3) CLINICAL TRIAL DESIGN AND IMPLEMENTATION. I HAVE DEVELOPED A STRONG TRAINING PLAN AND MENTORING TEAM, LED BY DRS. MARIAN TANOFSKY-KRAFF (CO-PRIMARY MENTOR), JASON LAVENDER (CO-PRIMARY MENTOR), JESSICA SCHLEIDER (MENTOR), AND PAIGE MCDONALD (MENTOR), AND A TEAM OF EXPERT CONSULTANTS. RESEARCH STRATEGY: THE OBJECTIVE OF THE STUDY IS TO DESIGN AND EVALUATE THE ACCEPTABILITY AND PRELIMINARY EFFICACY OF A VIRTUAL CBT-INFORMED SSI FOR LOC EATING DURING PREGNANCY. THE STUDY WILL FOLLOW THE KNOWLEDGE-TO-ACTION FRAMEWORK THAT GUIDES IMPLEMENTATION SCIENCE TO CONDUCT A TWO STUDY PROPOSAL. STUDY 1: I WILL ENGAGE PREGNANT WOMEN WHO EXPERIENCE LOC EATING TO IDENTIFY BARRIERS AND FACILITATORS TO DETECTING AND TREATING LOC EATING, AND USE THEIR INPUT TO DESIGN A VIRTUAL SSI. STUDY 2: PARTICIPANTS WILL BE RANDOMIZED TO EITHER THE SSI OR AN INFORMATION-ONLY CONDITION. THIS TRAINING AND RESEARCH PLAN WILL FORM THE BASIS FOR A FUTURE CLINICAL TRIAL TESTING THE EFFICACY OF THE SSI FOR IMPROVING LOC EATING AND WEIGHT OUTCOMES DURING PREGNANCY, TO BE PROPOSED IN AN R01 GRANT APPLICATION BEFORE THE END OF THE K23 AWARD.

REAL-TIME IN VIVO MEASUREMENT OF REACTIVE OXYGEN SPECIES: POTENTIAL MEASURE TO MITIGATE INJURY SEQUELAE OF HEMORRHAGING WARRIORS

THERAPEUTIC EFFECTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONIST ON COMBAT-INDUCED PROLIFERATIVE VITREORETINOPATH

ACTIVE REJECTION MICRO-PATCH SURVEILLANCE (ARMS) SYSTEM FOR VASCULARIZED COMPOSITE ALLOGRAFTS

LOCAL DELIVERY OF BIOENGINEERED MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES FOR TARGETED IMMUNOMODULATION IN VASCULARIZED COMPOSITE ALLOTRANSPLANTATION

WASTEWATER SURVEILLANCE - WALTER REED NATIONAL MILITARY MEDICAL CENTER ANTIMICROBIAL RESISTANCE PILOT

A NOVEL GRAFT EMBEDDED MACROPHAGE-TARGETED IMMUNOTHERANOSTIC...

MILITARY CARDIOVASCULAR OUTCOMES RESEARCH (MICOR)